国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (8): 475-479.doi: 10.3760/cma.j.issn.1673-422X.2019.08.006

• 论著 • 上一篇    下一篇

左亚叶酸钙、5-氟尿嘧啶联合表柔比星对胃癌患者应激反应及VEGF水平的影响

刘岩峰  郭辉  孙喜艳   

  1. 济宁医学院附属湖西医院肿瘤科,单县    274300
  • 收稿日期:2018-10-15 修回日期:2019-05-10 出版日期:2019-08-08 发布日期:2019-10-31
  • 通讯作者: 刘岩峰 E-mail:350729191@qq.com

Effects of calcium levofolinate and 5-fluorouracil combined with epirubicin on stress response and VEGF level in patients with gastric cancer

Liu Yanfeng, Guo Hui, Sun Xiyan   

  1. Department of Oncology, Huxi Hospital Affiliated to Jining Medical College, Shanxian 274300, China
  • Received:2018-10-15 Revised:2019-05-10 Online:2019-08-08 Published:2019-10-31
  • Contact: Liu Yanfeng E-mail:350729191@qq.com

摘要: 目的    探究左亚叶酸钙、5-氟尿嘧啶联合表柔比星对胃癌患者应激反应及血管内皮生长因子(VEGF)水平的影响。方法    选取济宁医学院附属湖西医院2016年4月至2018年3月收治的160例胃癌患者作为研究对象,采用随机数表法分为对照组和研究组,每组各80例,给予对照组患者表柔比星治疗,研究组则采用左亚叶酸钙、5-氟尿嘧啶联合表柔比星治疗。比较两组患者临床疗效及不良反应情况,并对两组患者治疗前后的血清VEGF水平及生命质量进行比较,同时检测应激反应指标皮质醇(Cor)、去甲肾上腺素(NE)、总抗氧化能力(TAC),对比两组患者的应激水平。结果    研究组患者总有效率为67.5%(54/80),明显优于对照组的45.0%(36/80),差异有统计学意义(χ2=8.229,P=0.004)。治疗后两组患者的生命质量均较治疗前显著升高,且研究组患者生命质量评分显著高于对照组(均P<0.001)。治疗后研究组患者Cor、NE、TAC分别为(239.27±19.63)μg/L、(258.46±18.31)ng/L、(11.01±0.77)KIU/L,明显低于对照组的(286.35±20.63)μg/L、(294.18±21.95)ng/L、(12.73±1.58)KIU/L,差异均具有统计学意义(t=10.003,P<0.001;t=9.476,P<0.001;t=6.984,P<0.001)。治疗后两组患者VEGF水平均较治疗前降低,且研究组患者VEGF水平明显低于对照组患者[分别为(39.4±0.9)pg/ml、(42.3±1.1)pg/ml,t=18.251,P<0.001]。对照组和研究组患者不良反应总发生率分别为82.5%(66/80)和48.8%(39/80),对照组不良反应发生率明显高于研究组,差异有统计学意义(χ2=20.197,P<0.001)。结论    左亚叶酸钙、5-氟尿嘧啶联合表柔比星治疗胃癌患者具有良好的临床疗效,不仅可以改善患者血清VEGF水平,还可以提高患者的生命质量,降低不良反应的发生率及机体应激反应,具有广泛的应用前景,值得在临床上进一步推广应用。

关键词: 胃肿瘤, 血管内皮生长因子类, 应激反应, 表柔比星, 左亚叶酸钙

Abstract: Objective  To investigate the effects of calcium levofolinate and 5-fluorouracil combined with epirubicin on stress response and vascular endothelial growth factor (VEGF) level in patients with gastric cancer. Methods  A total of 160 patients with gastric cancer treated in Huxi Hospital Affiliated to Jining Medical College from April 2016 to March 2018 were selected as research objects. All the patients were divided into two groups according to the random number table method and each group consisted of 80 cases. The control group was treated with epirubicin, while the study group was treated with calcium levofolinate and 5-fluorouracil combined with epirubicin. The clinical efficacy and adverse reactions of the two groups were observed and compared. The levels of VEGF and quality of life were compared before and after the treatment. The stress response indexes such as cortisol (Cor), norepinephrine (NE) and total antioxidant capacity (TAC) were detected, and the stress levels of the two groups were compared. Results  The total effective rate of the study group was 67.5% (54/80), which was significantly better than that of the control group [45.0% (36/80)], and the difference was statistically significant (χ2=8.229, P=0.004).  The quality of life of the two groups after the treatment was significantly higher than that before the treatment, and the quality of life scores of the study group were significantly higher than those of the control group (all P<0.001).  After the treatment, the levels of Cor, NE and TAC of the study group were (239.27±19.63) μg/L, (258.46±18.31) ng/L, (11.01±0.77) KIU/L, which were significantly lower than those of the control group [(286.35±20.63) μg/L, (294.18±21.95) ng/L, (12.73±1.58) KIU/L], and the differences were statistically significant (t=10.003, P<0.001; t=9.476, P<0.001; t=6.984, P<0.001). After the treatment, the VEGF levels of the two groups were lower than those before the treatment, and the VEGF level of the study group was significantly lower than that of the control group [(39.4±0.9) pg/ml vs. (42.3±1.1) pg/ml, t=18.251, P<0.001]. The total incidences of adverse reactions in the control group and the study group were 82.5% (66/80) and 48.8% (39/80), respectively. The incidence of adverse reactions in the control group was significantly higher than that in the study group, and the difference was statistically significant (χ2=20.197, P<0.001). Conclusion  Calcium levofolinate and 5-fluorouracil combined with epirubicin has a good clinical effect in treating patients with gastric cancer. It can not only improve the level of VEGF in the serum of patients, but also can improve the quality of life of patients, reduce the incidence of adverse reactions and body stress response. It has broad application prospects and is worthy of further promotion and application in clinic.

Key words: Stomach neoplasms, Vascular endothelial growth factors, Stress response, Epirubicin, Calcium levofolate